Antiemetic prophylaxis utilization in cancer patients in a hospital in Yogyakarta Special Region
Abstract
Chemotherapy is a type cancer treatment that uses anticancer drugs to inhibit cell division and kill cancer cells. Chemotherapy can cause side effect due to normal cells damages. The study aimed to investigate the use of antiemetic prophylaxis as premedication to prevent or reduce side effects on cancer patients undergoing chemotherapy. It was a observational study with retrospective design using medical records data of cancer patients who underwent chemotherapy in a hospital in Yogyakarta Special Region during May – September 2022. The results showed the cancer patients were dominated by women (85.71%) with ages 46-65 yr (63.27%) and stage III cancer (87.76%). There were 18 types of anticancer drugs and the most widely used drugs were doxorubicin 60 mg for the moderate emetogenic category and vinorelbine 37.5 mg for the low emetogenic category. The most widely used premedication regimen was a combination granisetron 3 mg, ondansetron 8 mg, and dexamethasone 10 mg regimen (72.45%). This combination was most often used for the cancer patients with the moderate emetogenic category (39 patients or 49.4%). However, not all the cancer patients undergoing chemotherapy with the low and moderate emetogenic anticancer drugs were administered the premedication. In conclusion, doxorubicin and vinorelbine are the most widely used for cancer patients undergoing chemotherapy in the hospital. In addition, a combination of granisetron, ondansetron, and dexamethasone is widely used as premedication.
References
Kim SJ, Baker CH, Kitadai Y, Nakamura T, Kuwai T, Sasaki T, et al. The pathogenesis of cancer metastasis: relevance to therapy. Princ Cancer Biother 2009; 17-40.
https://doi.org/10.1007/978-90-481-2289-9_2
WHO. Cancer (who.int). (2022). accessed on 24th June 2024
Riskesdas. Laporan Nasional RKD2018 FINAL. Badan Penelitian dan Pengembangan Kesehatan 674 (2018).
The Global Center Obsevatory. GLOBOCAN: Indonesia. (2020), accessed on 24th June 2024.
Sutopo DYH. Pengaruh pendidikan kesehatan terhadap perilaku sadari pada remaja putri sebagai deteksi dini kanker payudara. Poltekkes Kemenkes, Yogyakarta, 2020.
Kementerian Kesehatan RI. Panduan nasional penanganan kanker payudara. 2015.
National Cancer Institute. Nausea and vomiting related to cancer treatment (PDQ) - health professional version. National Cancer Institute.
https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq (2023). accessed on 24th June 2024
Amjad MT, Chidharla A, Kasi A. Cancer chemotherapy. StatPearls Publishing. 2023.
https://www.ncbi.nlm.nih.gov/books/NBK564367/
Pratiwi SR, Widianti E, Solehati T. Gambaran faktor-faktor yang berhubungan dengan kecemasan pasien kanker payudara dalam menjalani kemoterapi. J Pendidik Keperawatan Indones 2017; 3(2):167.
https://doi.org/10.17509/jpki.v3i2.9422
Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun 2021; 26:100278.
https://doi.org/10.1016/j.ctarc.2020.100278
Clemmons A, Gandhi A, Clarke A, Jimenez S, Le T, Ajebo G. Premedications for cancer therapies: a primer for the hematology/oncology provider. J Adv Pract Oncol 2021; 12(8):810-32.
https://doi.org/10.6004/jadpro.2021.12.8.4
Escobar Y, Cajaraville G, Virizuela JA, Álvarez R, Muñoz A, Olariaga O, et al. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer 2015; 23(9):2833-40.
https://doi.org/10.1007/s00520-015-2809-3
Suprayitno E, Prasetyo DY. Karakteristik kualitas hidup pasien dalam menjalani kemoterapi. JHeS (Journal of Health Studies) 2021; 5(2):73-83.
https://doi.org/10.31101/jhes.2325
Yi M, Li T, Niu M, Luo S, Chu Q, Wu K. Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. Biomark Res 2021; 9:55.
https://doi.org/10.1186/s40364-021-00310-y
Ratna R, Supadmi W, Yuniarti E. Kualitas hidup pasien kanker rawat jalan yang menjalani kemoterapi di RSUD Kota Yogyakarta. Maj Farm 2021; 17:278-86.
https://doi.org/ 10.22146/FARMASEUTIK.V17I2.62832
Lee JS, Bracci PM, Holly EA. Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use. Am J Epidemiol 2008; 168(3):278-88.
https://doi.org/10.1093/aje/kwn119
Priliana WK, Indriasari FN, Pratiwi E. Hubungan usia, jenis kelamin dan jenis kanker terhadap kualitas hidup anak dengan kanker. J Keperawatan Notokusumo 2018; 6(1):48-55.
Siwi A, Sumarni T, Fadly A, Hidayat A. Kualitas hidup pada pasien kanker yang menjalani kemoterapi. Prosiding Semin Nas Penelit dan Pengabdi Kd Masy 2021; 340-47.
White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med 2014; 46(3 Suppl 1):S7-15.
https://doi.org/10.1016/j.amepre.2013.10.029
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel) 2021; 13(17):4287.
https://doi.org/10.3390/cancers13174287
Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin's lymphoma. Med Sci (Basel) 2021; 9(1):5.
https://doi.org/10.3390/medsci9010005
Hutajulu SH, Prabandari YS, Bintoro BS, Wiranata JA, Widiastuti M, Suryani ND, et al. Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: a retrospective observational study. PLoS One 2022; 17(1):e0262468.
https://doi.org/10.1371/journal.pone.0262468
DiPiro JT, Yee GC, Haines LMPS, Nolin TD, Ellingrod V. Pharmacotherapy: a pathophysiologic approach, 11th Ed. Philadelphia: McGraw Hill., 2020).
Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27(suppl 5):v119-33.
https://doi.org/10.1093/annonc/mdw270
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2020; 34(28):3240-3261.
